[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiac-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiac-failure":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,41,60,99,126,160,181,206,236,262,293],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100588311","optimal-adult-heart-transplant-immunosuppression-with-microrna-levels-100588311",false,"NCT06939751","OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels","OPTIMAL","Inclusion Criteria:\n\n* Age ≥ 18 years at enrollment\n* Receipt of orthotopic heart transplant (OHT) within the prior 1 month ± 2 weeks\n* Planned follow-up at the transplant center for a minimum of one-year.\n* Patient able and willing to comply with the study visit schedule, study procedures, and study requirements.\n\nExclusion Criteria:\n\n* Recipient of a multi-organ transplant\n* History of prior solid organ transplant before the index heart transplant\n* Ongoing mechanical circulatory support or hemodynamic instability (e.g., inotrope or vasopressor therapy)\n* Ongoing need for renal replacement therapy and\u002For dialysis\n* Active infection requiring either a) hospitalization b) treatment with antimicrobial therapy or c) reduction in immunosuppression\n* Active rejection being treated with intravenous medications or plasmapheresis","ALL","18 Years","99 Years",{"count":20,"type":21},250,"ESTIMATED","3 Years","OBSERVATIONAL","This study aims to develop and refine a microRNA (miR) biomarker panel that can be used to phenotype net immune state after heart transplantation using circulating miRs (associated with drug doses and levels). These miRs will be used to characterize the overall immune state in adult heart transplant patients and predict patients that will go on to develop infection and rejection. MicroRNAs (miRs) are small, non-coding RNA molecules that regulate gene expression and serve as molecular biomarkers found in the circulation.",[26,27],"Cardiac Failure","Graft Rejection","RECRUITING","2026-04-20",{"date":31,"type":32},"2026-04-22","ACTUAL",{"date":34,"type":32},"2025-10-28",{"date":36,"type":21},"2032-01-01",{"name":38,"class":39},"Inova Health Care Services","OTHER",7,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":48,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":40},"100557036","optimal-pediatric-heart-transplant-immunosuppression-with-micrornas-100557036","NCT06532890","Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs","OPTIMA","Inclusion Criteria:\n\n* Age ≤ 18 years at time of transplant listing\n* Subject is within 10-50 days post-orthotopic heart transplant at time of enrollment.\n* Planned follow-up at the transplant center for a minimum of one-year.\n* Caregiver able and willing to comply with the study visit schedule, study procedures, and study requirements.\n\nExclusion Criteria:\n\n* Recipient of a multi-organ transplant\n* History of prior solid organ transplant before the index heart transplant\n* Ongoing mechanical circulatory support or hemodynamic instability after transplant\n* Active infection requiring either a) hospitalization or b) treatment with antimicrobial drugs (does not include prophylaxis for infection or suppressive antibiotics given after transplant)\n* History of treated rejection prior to study enrollment\n* Inability to collect specified blood volume after enrollment and prior to 50 days post-transplant",{"count":49,"type":21},150,"This study aims to discover circulating microRNAs (associated with drug doses and levels) that can be used to characterize the overall immune state in pediatric heart transplant patients and predict patients that will go on to develop infection and rejection. MicroRNAs (miRs) are small, non-coding RNA molecules that regulate gene expression and serve as molecular biomarkers found in the circulation.",[26,27],"2026-03-24",{"date":54,"type":32},"2026-03-25",{"date":56,"type":32},"2025-02-06",{"date":58,"type":21},"2029-10-01",{"name":38,"class":39},{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":66,"minAge":17,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":78,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100564422","social-prescribing-to-improve-adherence-and-outcomes-in-women-with-heart-failure-100564422","NCT06628973","Social Prescribing to Improve Adherence and Outcomes in Women With Heart Failure","Inclusion Criteria:\n\n* Women\n* 18 years of age or older\n* Documented HF of any etiology\n* Valid personal health identifier\n* Two or more points on the weighted SPARK questionnaire\n\nExclusion Criteria:\n\n* Patients not meeting inclusion criteria\n* Do not take HF medications\n* Not residents of the province where they are being followed or who have opted out from their provincial health registry\n* Patients with severe cognitive impairment or other conditions that significantly impact the ability to participate in SP will also be excluded.","FEMALE",{"count":68,"type":21},200,"INTERVENTIONAL",[71],"NA","Background: Heart Failure (HF) is the second most common cause of hospitalizations for women in North America. Non-adherence to guideline-directed medical therapy (GDMT) is associated with 50% of all treatment failures and high rates of hospitalizations and death. A recent Canadian study showed that adherence to three or more GDMT medications occurred in only 20% of Canadian HF patients. Despite clear guidelines on the pharmacologic management of HF and the introduction of new and effective drugs, adherence to GDMT in women with HF is low. Furthermore, the rates of hospitalizations have not improved in Canada over the last decade, and mortality in Canadian women with HF remains high. One explanation may be that social determinants of health (SDOH), which are known to be strong predictors of both adherence and adverse outcomes in HF, have not specifically been targeted to improve either adherence or outcomes in HF. Social prescribing (SP) is an innovative, non-medical intervention that aims to improve health by addressing SDOH. However, whether using SP to LINK clinical and social services for the benefit of socially vulnerable HF women can improve outcome is unknown. By targeting SDOH, which are strong predictors of adherence and outcomes in HF, and which have been shown to disproportionately disfavor women, SP has the potential to significantly improve medication adherence, quality of life and outcomes in women with HF.\n\nObjectives: The overall aim of this study is to assess whether SP, through individualized, SDOH-targeted interventions, can improve adherence and quality of life in Canadian women with HF and at high risk for no adherence. Primary objective: To determine whether SP can improve adherence to GDMT. Secondary objective: To determine whether SP can improve quality of life.\n\nMethods: This is an intention to treat, multicenter (five centers), and open-labeled, randomized clinical trial. Women with HF with two or more points on a weighted SDOH questionnaire (SPARK tool) will be randomly assigned to either SP or control group. Women in the SP group will meet with a link worker (LW) who will perform SP. SP will consist of personalized referrals to non-medical supports or services based on women's specific SDOH-related vulnerabilities and social needs. SP will address social needs such as issues with income, unemployment, transportation, mobility, dependents, housing, loneliness, mental health, health literacy, medication management and medical appointment schedules. Social prescriptions will be based on the interview conducted by the LW and will prioritize SDOH-related vulnerabilities identified on the SPARK questionnaire. Participants in the control group will receive standard care as is typically offered in the current specialized HF clinic in the participating centers. Controls will not meet with a LW, but, as usual, their physician or treating team may refer them to any specialists or services deemed necessary.\n\nOutcome measures: The primary outcome will be adherence to GDMT measured with PDC obtained from provincial administrative databases and the secondary outcome will be quality of life measures including physical limitations, social limitations, as measured with the Kansas City Cardiomyopathy Questionnaire (KCCQ-12).\n\nSample size Calculations: The sample size was calculated using the primary outcome of adherence to GDMT measured with PDC as a continuous variable. In one observational study on adherence to HF medications which compared women and males adherence using PDCs, adherence in women was 63% with a SD of 23%. The impact of an absolute increase of 10% in PDC on clinical end points was considered significant. Using an alpha of 0.05 and a power of 0.80, a minimum of 166 participants would be needed to detect a statistically significant difference. Based on pilot data, the proportion of women followed in heart failure clinics is 28% and the proportion of eligible women (i.e. 1 point or more on the SPARK questionnaire) is about 30%. Considering a 30% refusal rate and a 5% dropout rate (intention to treat with registry based outcome), the five chosen centers should totalize 188 participants. The secondary outcome, the KCCQ, is a continuous variable for which a change of five points or more (5%) is considered clinically significant. Using an alpha of 0.05 and a power of 0.80, 126 patients would be required to detect such a difference.\n\nSignificance: SP holds immense potential for women with HF by addressing critical gaps in care. SP may help bridge the gap between healthcare providers and community resources, providing tailored support addressing SDOH that disproportionately affect women with HF. SP has the potential to significantly enhance adherence to GDMT, which has been shown to greatly, reduce hospitalizations and mortality in this vulnerable population.",[74,26,75,76,77],"Heart Failure","Heart Decompensation","Congestive Heart Failure(CHF)","Myocardial Failure",[74,79,80,81,82,83,84,85,86,87,88],"Social Determinants of Health","Adherence","Social Prescribing","Hospitalizations","Readmissions","Sex","Gender","Quality of Life","Congestive Heart Failure","Women","2026-02-18",{"date":91,"type":32},"2026-02-20",{"date":93,"type":32},"2025-10-23",{"date":95,"type":21},"2028-12-31",{"name":97,"class":39},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",2,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":98},"100624885","cardiac-remodelling-following-endovascular-repair-of-the-aorta-100624885","NCT07415447","Cardiac Remodelling Following Endovascular Repair of the Aorta","EVACaRe","Inclusion Criteria:\n\n\\- Patients over 18-year-old, with degenerative arch, descending thoracic or abdominal aortic aneurysms, penetrating aortic ulcers or intramural hematomas managed with total EVAR in elective setting.\n\nExclusion Criteria:\n\n* Heart failure with an ejection fraction \\\u003C35 vs 50% or New York Heart Association (NYHA) class III and IV.\n* LV wall motion abnormality.\n* Moderate to severe valve disease.\n* History of (or expected within the study period) cardiac\u002Faortic surgery.\n* Coronary artery disease.\n* Atrial fibrillation.\n* Congenital heart disease.\n* Connective tissue disorders.\n* Chronic kidney disease (eGFR \\\u003C30 mL\u002Fmin\u002F173 m2).\n* Moderate to severe pulmonary disease as indicate either by post bronchodilator FEV1 (%predicted) \\\u003C50% or Modified Medical Research Council Dyspnoea Scale (mMRC) 3-4.\n* CMR contraindications (non-compatible pacemakers and metal implants, and claustrophobia).",{"count":107,"type":21},40,"To assess the effects of endovascular aortic repair on cardiac morphology and function",[26,110],"Aortic Disease",[112,113,114,115],"cardiac","failure","aortic","disease","2026-02-12",{"date":118,"type":32},"2026-02-17",{"date":120,"type":32},"2025-09-01",{"date":122,"type":21},"2027-09-01",{"name":124,"class":125},"Lisbon Academic Medical Center - Centro Académico de Medicina de Lisboa","NETWORK",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":136,"conditions":137,"keywords":144,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":159},"100343574","recovery-from-icuaw-following-severe-respiratory-and-cardiac-failure-100343574","NCT03753412","Recovery From ICUAW Following Severe Respiratory and Cardiac Failure","Prospective Observational Study Regarding the Determinants of Functional Disability and Quality of Life in Patients Recovering From Severe Acute Cardiac or Respiratory Failure Considered for Mechanical Cardiorespiratory Support (CLEVERER)","CLEVERER","Inclusion Criteria:\n\n* Above the age of 18\n* Adults with severe cardio-respiratory failure requiring ECMO.\n* Adults who have had personal and professional consultees agree to enrol them in the trial.\n\nExclusion criteria:\n\n* Previous Stroke\n* Neuromuscular disease\n* Malignancy\n* Underlying neuromuscular disease\n* paediatrics",{"count":135,"type":21},100,"To observe and identify determinants of recovery from intensive care unit-acquired weakness (ICUAW) following a severe cardiorespiratory failure requiring extra-corporeal membrane oxygenation (ECMO). Additionally, to discover the effects of ICUAW on physical function and health-related quality of life (HRQoL) after critical illness. CLEVERER is a clinical observational pilot study.",[138,139,140,141,26,142,143],"Intensive Care Unit Syndrome","Intensive Care Neuropathy","Intensive Care (ICU) Myopathy","Acute Respiratory Distress Syndrome","Respiratory Failure","Critical Illness Myopathy",[145,146,147,148,149],"Extra Corporeal Membrane Oxygenation (ECMO)","Intensive Care Unit Acquired Weakness (ICUAW)","Critical Illness Polyneuromyopathy (CIPM)","Ultrasound (US)","Health Related Quality of Life (HRQoL)","2026-01-05",{"date":152,"type":32},"2026-01-07",{"date":154,"type":32},"2019-04-09",{"date":156,"type":21},"2026-09-26",{"name":158,"class":39},"Barts & The London NHS Trust",1,{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":169,"conditions":170,"keywords":171,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":159},"100618656","study-of-platelet-population-changes-under-circulatory-support-with-ecmo-100618656","NCT07334457","Study of Platelet Population Changes Under Circulatory Support With ECMO","ECMO-POP","Inclusion Criteria:\n\n* Adult patient (≥18 years) treated in one of the intensive care units of the Anesthesia and Intensive Care Department at Strasbourg University Hospital.\n* Implanted with veno-arterial or veno-venous ECMO within the previous 24 hours.\n\nExclusion Criteria:\n\n* Subject who has expressed their opposition to participating in the study.\n* Subject under legal protection.\n* Subject under guardianship or curatorship.",{"count":168,"type":21},75,"Advances in flow cytometry techniques have led to a better understanding of platelet phenotypes and have revealed the existence of four major platelet populations with distinct functional properties (native, proaggregating, procoagulating, or apoptotic). These phenotypes have a significant impact on the hemostatic capacity of blood platelets, and a proportional change in these populations during ECMO treatment could, at least in part, contribute to the observed complications.",[26,142],[26,142],"2025-12-30",{"date":174,"type":32},"2026-01-12",{"date":176,"type":32},"2025-03-11",{"date":178,"type":21},"2027-03-11",{"name":180,"class":39},"University Hospital, Strasbourg, France",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":69,"phases":191,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":205},"100577082","phase-4-landiolol-in-mitral-valve-surgery-100577082","NCT06793670","Landiolol in Mitral Valve Surgery","The Use of Landiolol in Mitral Valve sUrgery: a raNdomized, Controlled, Double-blind triAl (LUNA)","LUNA","Inclusion Criteria:\n\n* Older than 18 years;\n* Elective mitral valve repair or replacement surgery with planned cardiopulmonary bypass via midline sternotomy or minithoracotomy;\n* Preoperative evidence of left ventricular end-systolic diameter \\>40 mm and\u002For left ventricular end-diastolic diameter \\>60 mm and\u002For left ventricular ejection fraction\\\u003C60%;\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Need for preoperative dialysis;\n* Hepatic dysfunction (defined as Child-Pugh class C);\n* History of previous unusual response to beta-blockers;\n* Urgent or emergency surgery;\n* Patient already in need of mechanical circulatory support before surgery (except for IABP);\n* Pregnancy as documented by a pregnancy test performed in the last 72h before surgery;\n* Patients with preoperative evidence of hypernatremia (serum sodium concentration: \\> 160 mmol\u002FL);\n* Patients with preoperative evidence of hyperchloremia (serum chloride concentration: \\>115 mmol\u002FL);\n* Patients with hypersensitivity to the active substance or to any of the excipients;\n* Patients with severe bradycardia (less than 50 beats per minute) sick sinus syndrome, severe atrioventricular nodal conductance disorders or 2nd -3rd degree atrioventricular block and without a pacemaker;\n* Patients with cardiogenic shock, severe hypotension (MAP\\\u003C50 mmHg), decompensated heart failure or severe pulmonary hypertension (PAPs \\>70 mmHg);\n* Patients with non-treated phaeochromocytoma;\n* Patients with acute asthmatic attack;\n* Patients with severe, uncorrectable metabolic acidosis.\n* Participation in a clinical trial in which an investigational drug was administered within 30 days of screening or within the 5 half-lives of the study drug, whichever is longer.\n* Planned use of ultra-short acting beta-blockers as intraoperative cardiac protective strategy.\n* Refusal or inability to sign the informed consent.",{"count":190,"type":21},1500,[192],"PHASE4","Chronic mitral regurgitation is the most common valvular abnormality worldwide, it occurs in 10% of the general population and its prevalence increases with age. When left untreated, it can lead to left ventricular dysfunction and cause disabling symptoms (e.g., fatigue and dyspnea), life-threatening complications (e.g., ventricular dilation, congestive heart failure) and death. Surgical correction of chronic mitral regurgitation before irreversible changes happen can be curative. Open surgical valve repair or replacement are accomplished through cardiopulmonary bypass and cardioplegic arrest. Myocardial protection is essential to guarantee an uneventful perioperative course since a not-well protected heart may lead to postoperative low-cardiac output syndrome. This occurs in 30% of high-risk patients who undergo elective cardiac surgery and is associated with 20% mortality. Cardioplegia preserves the heart during ischemic arrest by reducing its metabolic demand. The most effective cardioplegia for protection in adult cardiac surgery remains unknown and improving the protection of the heart during the ischemic arrest may potentially improve patients' postoperative outcomes. Pharmacological adjuvants to the cardioplegic solutions have been tested to mitigate the ischaemic-reperfusion injury following cardiac surgery. Ultra-short acting beta-blockers (e.g., esmolol, landiolol) decrease intraoperative myocardial metabolic demand and suppress the sympathetic response to surgical stimuli while exhibiting limited adverse effects. Few studies with limited sample size investigated the role of ultra-short acting beta-blockers in reducing perioperative ischaemia and arrhythmia after cardiac surgery. When ultra-short acting beta-blockers were administered before aortic cross-clamping and as cardioplegia adjuvant we observed a trend towards a reduction in postoperative low-cardiac output syndrome (13\u002F98 vs 6\u002F102; p=0.08) and in the rate of hospital re-admission at one year (26\u002F95 v 16\u002F96, p=0.08) with an increase in the number of patients with ejection fraction \\>60% at hospital discharge (4\u002F95 vs 11\u002F92, p=0.06) (Zangrillo 2021). However, despite a growing body of literature exploring the role of ultra-short acting beta-blockers in enhancing myocardial protection during on-pump cardiac surgery, further high-quality evidence is needed before this practice can be established as standard routine care. Hence, we designed a randomized, placebo-controlled trial involving 1500 patients undergoing open mitral valve surgery to assess the effect of administering landiolol as cardioplegia adjuvant to reduce the occurrence of postoperative low-cardiac output syndrome. Successful results would have a significant impact on short and long-term complications.",[26,195],"Low Cardiac Output Syndrome","2025-12-19",{"date":198,"type":32},"2025-12-29",{"date":200,"type":32},"2025-01-28",{"date":202,"type":21},"2027-12",{"name":204,"class":39},"Università Vita-Salute San Raffaele",13,{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":69,"phases":216,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":159},"100554740","phase-3-the-effect-of-phosphocreatine-on-medical-emergency-team-met-treated-patients-100554740","NCT06503016","The Effect of phoSPHocreatine on mEdical Emergency Team (Met) tREated Patients","The Effect of phoSPHocreatine on mEdical Emergency Team (Met) tREated Patients: a Randomized Clinical Trial Protocol","SPHERE","Inclusion Criteria:\n\n1. Admitted in hospital (but outside ICU)\n2. Age\\>=18 years\n3. Written informed consent\n4. Serum creatinine \\\u003C=2 mg\u002Fdl\n5. Patient with impending or underlying cardiac failure or cardiac arrest, irrespectively of the primitive organ failure, and the Medical Emergency Team (MET) is called upon at least one of the following:\n\n   1. Threatened airways;\n   2. Respiratory arrest;\n   3. Respiratory rate \\\u003C5 or \\>36 breaths per min;\n   4. Pulse rate \\\u003C40 or \\>140 beats per min;\n   5. Systolic blood pressure \\\u003C 90 mm Hg;\n   6. Sudden fall in level of consciousness;\n   7. Fall in Glasgow coma scale of \\> 2 points.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years;\n2. Ongoing cardiac massage;\n3. Current hospital admission from a care nursing facility;\n4. Planned discharge to a care nursing facility;\n5. Reasons for withdrawal of life-sustaining therapy;\n6. History of kidney transplantation;\n7. Solitary kidney (by any reason);\n8. Serum Creatinine \\> 2 mg\u002Fdl;\n9. Immediate need for ICU admission;\n10. Known allergy to PCr;\n11. Pregnancy;\n12. Previous enrollment and randomization into this trial;\n13. Administration of PCr in the previous 30 day.",{"count":215,"type":21},400,[217],"PHASE3","Unexpected deaths and unplanned intensive care unit (ICU) admissions are common during hospital stay and are often preceded by warning abnormalities in patients' vital signs. These abnormalities trigger Medical Emergency Team (MET) activation and up to 15% of patients visited by the MET is admitted to the ICU with an overall hospital stay after the MET intervention of approximately 2 weeks. Phosphocreatine (PCr) is a natural energy-buffering molecule associated with signals of mortality reduction in patients with acute cardiac conditions (according to meta-analytic finding from our group) and with encouraging beneficial effects on other acute organ failures (e.g. brain). The investigators designed a multi-center, randomized, placebo-controlled trial to confirm the promising beneficial effects of PCr in hospitalized patients. The investigators expects a reduction in hospital stay (measured as an increase in days alive and out of hospital at 30 days) when PCr is added to standard treatment in patients requiring MET intervention.",[220,221,222,142,223,224,225,226,26,227],"Hypotension","Consciousness, Level Altered","Airway Disease","Tachypnea","Bradypnea","Tachycardia","Bradycardia","Cardiac Arrest","2025-08-05",{"date":230,"type":32},"2025-08-06",{"date":232,"type":32},"2024-10-08",{"date":234,"type":21},"2026-07",{"name":204,"class":39},{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":243,"enrollmentInfo":244,"targetDuration":246,"studyType":23,"phases":4,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":261},"100376602","a-post-market-surveillance-study-of-the-hemovent-extracorporeal-cardiopulmonary-support-systemthe-mobybox-trial-100376602","NCT04183660","A Post Market Surveillance Study of the Hemovent Extracorporeal Cardiopulmonary Support System:The MOBYBOX Trial","A Post Market Surveillance Study of the Hemovent Extracorporeal Cardiopulmonary Support System for Cardiac and Respiratory Support: The MOBYBOX Trial","Inclusion Criteria:\n\n* Diagnosed with cardiac, respiratory or cardiorespiratory failure or imminent failure and 1 of the 5 following sets of findings:\n\n  1. A Murray score ≥ 3.0 and\u002For severe hypoxemia with A PaO2\u002FFIO2 \\> 100 mm on 0.9 FIO2;\n  2. Uncompensated hypercapnia with pH \\\u003C7.2 despite a Pplateau \\> 30 cm H20;\n  3. Significant air leak\u002Fbronchopleural fistula;\n  4. Need for intubation in a patient on lung transplant list;\n  5. Immediate\u002Frisk of cardiac or respiratory collapse (pulmonary embolus, blocked airway, blocked blood flow, unresponsive to optimal care);\n* Written consent of the patient or the legal guardian or external consulting physician as designated and approved by the Ethics Committee.\n\nExclusion Criteria:\n\n* High pressure ventilation (FIO2 \\> 0.9 and Pplateau \\> 30 cm H2O) or high FIO2 requirements for more than 7 days;\n* Severe intracranial bleeding, which precludes the use of anticoagulation therapy or any other inability to be anticoagulated\n* Excessive weight (\\> 180 Kg)\n* Severe irreversible brain injury (e.g., hypoxic brain injury)\n* Inability to accept blood products;\n* Any condition or organ dysfunction that would limit the likelihood of overall benefit from ECMO, such as severe, irreversible brain injury, hepatic and\u002For renal failure, or untreatable metastatic cancer;\n* Immunosuppression with an absolute neutrophil count \\\u003C 400\u002Fmm3;\n* Patient has been treated with ECMO ≤ 48 hours.\n* For veno-veno ECMO in the setting of respiratory failure the following exclusion criteria apply:\n* Severe pulmonary hypertension (mPAP \\> 50 mm Hg)\n* Severe right or left sided heart failure (EF \\\u003C 25%)\n* For veno-arterial ECMO in the setting of cardiac insufficiency:\n* Severe aortic regurgitation\n* Aortic dissection.\n* The patient is moribund, or the patient has severe or deteriorating damage in critical body systems.\n* Patient is participating in an investigational drug or device study trial that has not reached the primary endpoint or that interferes with the current study endpoints.\n* Any condition that in the judgment of the investigators would interfere with the subject's ability to provide informed consent, comply with study instructions, place the subject at increased risk, or which might confound interpretation of study results.","80 Years",{"count":245,"type":21},60,"30 Days","The purpose of this study is to evaluate prospectively the safety and performance of the MOBYBOX System in the veno-arterial configuration in patients with cardiorespiratory failure or in the veno-venous configuration in patients with severe respiratory failure.",[26,142,249,250],"Cardio-Respiratory Failure","Imminent Cardiorespiratory or Respiratory Failure","2025-05-27",{"date":253,"type":32},"2025-05-31",{"date":255,"type":32},"2024-04-30",{"date":257,"type":21},"2026-12",{"name":259,"class":260},"Hemovent GmbH","INDUSTRY",4,{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":69,"phases":272,"briefSummary":274,"conditions":275,"keywords":281,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":40},"100415967","phase-2-effect-of-xenon-on-brain-injury-after-aneurysmal-subarachnoid-hemorrhage-100415967","NCT04696523","Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage","Effect of Xenon on Brain Injury, Neurological Outcome and Survival in Patients After Aneurysmal Subarachnoid Hemorrhage","Xe-SAH","Inclusion Criteria:\n\nTo be considered eligible to participate in this study, a SAH subject must meet the inclusion criteria listed below:\n\n1. Informed consent obtained from the next of kin or legal representative\n2. Aneurysmal subarachnoid hemorrhage visible on CTA or DSA.\n3. Deterioration of consciousness to Hunt-Hess 3-5\n4. Age of ≥ 18 years\n5. Intubated.\n6. GCS 3-12 obtained off neuromuscular blocking agents\n7. Xenon treatment can be started within 6 hours after onset of SAH symptoms\n\nExclusion Criteria:\n\nAn aSAH subject may not be enrolled in the trial if he\u002Fshe meets any one of the exclusion criteria below:\n\n1. Acute or chronic traumatic brain injury\n2. Maximum diameter of intracerebral hemorrhage \\> 2.5 cm\n3. Pneumothorax or pneumomediastinum,\n4. Acute lung injury requiring ≥ 60% FIO2 (fraction of inspired oxygen).\n5. Systolic arterial pressure \\\u003C 80 mmHg or mean arterial pressure \\\u003C 60 mmHg for over 30 min period\n6. Bilaterally fixed and dilated pupils\n7. Positive pregnancy test, known pregnancy, or current breast-feeding\n8. Neurological deficiency due to traumatic brain injury or other neurological illness\n9. Imminent death or current life-threatening disease\n10. Current enrollment in another interventional study\n11. The subject is known to have clinically significant laboratory abnormality, medical condition (such as decompensated liver disease or severe chronic obstructive pulmonary disease), or social circumstance that, in the investigator's opinion, makes it inappropriate for the subject to participate in this clinical trial.\n12. Presence of implants or foreign bodies which are not known to be MRI safe",{"count":271,"type":21},160,[273],"PHASE2","An investigator-initiated clinical drug study\n\nMain Objective:\n\nTo explore neuroprotective properties of xenon in patients after aneurysmal subarachnoid hemorrhage (SAH).\n\nPrimary endpoint: Global fractional anisotropy of white matter of diffusion tensor imaging (DTI). Hypothesis: White matter damage is less severe in xenon treated patients, i.e. global fractional anisotropy is significantly higher in the xenon group than in the control group as assessed with the 1st magnetic resonance imaging (MRI).\n\nAfter confirmation of aSAH and obtaining a signed assent subjects will be randomized to the following groups:\n\nControl group: Standard of Care (SOC) group: Air\u002Foxygen and Normothermia 36.5-37.5°C; Xenon group: Normothermia 36.5-37.5°C +Xenon inhalation in air\u002Foxygen for 24 hours. Brain magnetic resonance imaging techniques will be undertaken to evaluate the effects of the intervention on white and grey matter damage and neuronal loss. Neurological outcome will be evaluated at 3, 12 and 24 months after onset of aSAH symptoms Investigational drug\u002Ftreatment, dose and mode of administration: 50±2 % end tidal concentration of inhaled xenon in oxygen\u002Fair.\n\nComparative drug(s)\u002Fplacebo\u002Ftreatment, dose and mode of administration: Standard of care treatment according to local and international consensus reports.\n\nDuration of treatment: 24 hours\n\nAssessments:\n\nBaseline data Information that characterizes the participant's condition prior to initiation of experimental treatment is obtained as soon as is clinically reasonable. These include participant demographics, medical history, vital signs, oxygen saturation, and concentration of oxygen administered.\n\nAcute data The collected information will contain quantitative and qualitative data of aSAH patients, as recommended by recent recommendations of the working group on subject characteristics, and including all relevant Common Data Elements (CDE) can be applied. Specific definitions, measurements tools, and references regarding each SAH CDE can be found on the weblink here: https:\u002F\u002Fwww.commondataelements.ninds.nih.gov\u002FSAH.aspx#tab=Data\\_Standards.",[276,277,278,279,280,26],"Subarachnoid Hemorrhage, Aneurysmal","Cerebral Injury","Cerebral Ischemia","Cerebral Infarction","Cardiac Event",[282],"xenon, neuroprotection, aneurysmal subarachnoid hemorrhage","2025-04-28",{"date":285,"type":32},"2025-05-01",{"date":287,"type":32},"2025-04-22",{"date":289,"type":21},"2029-12-31",{"name":291,"class":292},"Turku University Hospital","OTHER_GOV",{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":300,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":302,"conditions":303,"keywords":4,"overallStatus":306,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":4},"100564670","non-invasive-monitoring-of-mixed-venous-oxygen-saturation-using-the-capnodynamic-method-in-adults-100564670","NCT06632197","Non-invasive Monitoring of Mixed Venous Oxygen Saturation Using the Capnodynamic Method in Adults","CAPNO-SVO2","Inclusion Criteria:\n\n* Age \\> 18 years\n* Not participating in any other interventional study at the time of the study.\n* Patients under controlled mechanical ventilation in passive conditions.\n* Situations where the responsible physician deems that, for the benefit of clinical management and therapeutic decision-making, the patient would benefit from the placement of a pulmonary artery catheter (Swan-Ganz) and\u002For monitoring of central or mixed venous saturation.\n* Obtaining informed consent.\n\nExclusion Criteria:\n\n* Failure to obtain informed consent.\n* No need for invasive mechanical ventilation.",{"count":301,"type":21},25,"The objective of this study is to compare the accuracy and correlation of the capnodynamic method for measuring mixed venous oxygen saturation (SvO2) with the standard reference method (pulmonary artery catheter), with the potential for the capnodynamic method to replace the traditional method in selected cases.",[304,26,305],"Ventilatory Failure","Mechanical Ventilation Pressure High","NOT_YET_RECRUITING",{"date":308,"type":32},"2024-10-10",{"date":310,"type":21},"2024-12",{"date":312,"type":21},"2025-08",{"name":314,"class":39},"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa"]